Datapoint: Pfizer Scores Multiple Myeloma Nod for Elrexfio

The FDA last week approved Pfizer’s Elrexfio for the treatment of relapsed or refractory multiple myeloma in adult patients that have received at least four prior lines of treatment, “including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.” The drug will face off against Johnson & Johnson’s Tecvayli, another BCMA-directed bispecific antibody. Both drugs are administered as subcutaneous injections, though Elrexfio may edge out Tecvayli on convenience. The J&J therapy requires weekly administration, while Elrexfio is given biweekly. For the treatment of multiple myeloma, Tecvayli currently holds covered or better status for 85% of all insured lives under the medical benefit. About 21% of lives have preferred access to Tecvayli.

SOURCE: MMIT Analytics, as of 8/21/23

0

0

0 Comments

0

0

• Datapoint